CRIS Current Research Information System

DE ROSA, FRANCESCO
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 1.543
EU - Europa 1.267
AS - Asia 1.047
AF - Africa 79
SA - Sud America 60
OC - Oceania 3
Totale 3.999
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 1.523
IT - Italia 316
SG - Singapore 307
CN - Cina 294
GB - Regno Unito 281
VN - Vietnam 262
SE - Svezia 145
DE - Germania 123
IN - India 68
RU - Federazione Russa 63
HK - Hong Kong 60
IE - Irlanda 58
FR - Francia 55
CH - Svizzera 53
BR - Brasile 46
NL - Olanda 41
ZA - Sudafrica 30
FI - Finlandia 29
TG - Togo 29
UA - Ucraina 29
EE - Estonia 18
BG - Bulgaria 17
JP - Giappone 17
JO - Giordania 16
BE - Belgio 11
CA - Canada 11
SC - Seychelles 7
AR - Argentina 6
AT - Austria 6
CI - Costa d'Avorio 6
IR - Iran 6
PL - Polonia 6
CL - Cile 5
ID - Indonesia 5
NG - Nigeria 5
MX - Messico 4
NI - Nicaragua 4
RO - Romania 4
AU - Australia 3
GR - Grecia 3
MY - Malesia 3
ES - Italia 2
LB - Libano 2
AE - Emirati Arabi Uniti 1
BD - Bangladesh 1
CO - Colombia 1
CZ - Repubblica Ceca 1
DM - Dominica 1
DZ - Algeria 1
EC - Ecuador 1
EG - Egitto 1
HR - Croazia 1
HU - Ungheria 1
KR - Corea 1
KZ - Kazakistan 1
LT - Lituania 1
LU - Lussemburgo 1
PE - Perù 1
PH - Filippine 1
PT - Portogallo 1
SK - Slovacchia (Repubblica Slovacca) 1
TW - Taiwan 1
UZ - Uzbekistan 1
Totale 3.999
Salva come PNG Salva come JPEG
Città #
Southend 260
Singapore 200
Chandler 188
Ashburn 179
Dong Ket 162
Santa Clara 114
Fairfield 95
Princeton 72
Wilmington 65
Hong Kong 59
Dublin 58
Houston 54
Beijing 51
Bern 49
New York 48
Ann Arbor 45
Woodbridge 41
Bologna 39
Seattle 34
Ho Chi Minh City 33
Boardman 30
Lomé 29
Westminster 28
Nanjing 27
Padova 27
Rome 27
Cambridge 26
Helsinki 25
Milan 24
Medford 23
Jinan 22
Los Angeles 20
Hanoi 19
Dallas 18
Shenyang 18
Sofia 17
Tokyo 17
Saint Petersburg 16
Amman 15
Mülheim 14
Turin 14
Berlin 12
San Diego 12
Brussels 11
Hebei 11
Buffalo 10
Changsha 10
Florence 9
Jacksonville 9
Mountain View 9
Pune 9
Tianjin 9
Jiaxing 8
Ravenna 8
Frankfurt am Main 7
Fremont 7
Guangzhou 7
Redwood City 7
Shanghai 7
São Paulo 7
Abidjan 6
Nanchang 6
Torino 6
Toronto 6
Abeokuta 5
Dearborn 5
Kuban 5
Monmouth Junction 5
Mumbai 5
Ninh Bình 5
Norwalk 5
Redondo Beach 5
Rio de Janeiro 5
Taizhou 5
Ardabil 4
Bari 4
Falls Church 4
Lanzhou 4
Managua 4
Paris 4
Phoenix 4
The Dalles 4
Turku 4
Warsaw 4
Wuhan 4
Xi'an 4
Brooklyn 3
Can Tho 3
Castelfranco Emilia 3
Falkenstein 3
Forlì 3
Haikou 3
Kunming 3
Munich 3
Ningbo 3
Nuremberg 3
San Mateo 3
San Venanzo 3
Taiyuan 3
Zhengzhou 3
Totale 2.635
Salva come PNG Salva come JPEG
Nome #
Follow-up del cancro del pancreas esocrino 400
Adjuvant systemic chemotherapy after putative curative resection of colorectal liver and lung metastases. 224
Antitumoral efficacy of the protease inhibitor gabexate mesilate in colon cancer cells harbouring KRAS, BRAF and PIK3CA mutations 212
Antiprotease strategy in pancreatic cancer treatment: emergence from a preclinical study. 209
Second surgery or chemotherapy for relapse after radical resection of colorectal cancer metastases. 191
Asbestos: a putative risk factor for intrahepatic cholangiocarcinoma 174
Second-line chemotherapy in patients with biliary tract cancer. 145
Metronomic capecitabine in advanced hepatocellular carcinoma patients:a phase II study. 143
High prevalence of asbestos exposure in bile duct cancer patients 139
EXPOSURE TO ASBESTOS: A PUTATIVE UNKNOWN RISK FACTOR FOR INTRAHEPATIC CHOLANGIOCARCINOMA 138
Impact of adjuvant chemotherapy on time to relapse in cholangiocarcinoma. 137
KRAS and BRAF mutational status as selective criteria for targeted therapy in cholangiocarcinoma. 136
Clinical safety and efficacy of adjuvant chemotherapy in radically resected cholangiocarcinoma patients. 128
Effect of the serine proteases inhibitor gabexate mesylate (GM) on the activity of gemcitabine (G) in cell lines of pancreatic cancer (PC) 128
Role of adjuvant chemoradiotherapy (CRT) and chemotherapy alone in pancreatic cancer: experience in 25 patients. 124
The Protease Inhibitor Gabexate Mesylate Reduces Invasiveness and Angiogenesis in Pancreatic Cancer Cell Lines, Enhancing Gemcitabine Action 123
Irinotecan toxicity: genes or intestinal microflora? 121
Second-line chemotherapy in biliary tract cancer patients. 120
The follow-up issues: from the necessity to the opportunity 117
High-resolution genomic profiling of Philadelphia chromosome-positive (Ph+) acute lymphoblastic leukemia (ALL) patients identified novel recurrent copy number variations involved in both pathogenesis and resistance to tyrosine kinase inhibitors 117
Feasibility of triplets (5-FU, oxaliplatin and irinotecan based) in front and subsequent lines of metastatic colorectal cancer patients. 115
Genome wide analysis of Philadelphia positive (Ph+) acute lymphoblastic leukemia (ALL) reveals a recurring deletion of VPREB1 gene which affects B-cell differentiation 113
Metronomic capecitabine as second-line treatment for patients with hepatocellular carcinoma with preserved liver function: A phase II study. 112
Metronomic capecitabine as second-line treatment after sorafenib for hepatocelllular carcinoma. 109
Metronomic capecitabine in advanced hepatocellualr cacinoma patients who have failed sorafenib: a phase II study 103
IMPACT OF MULTIDISCIPLINARY APPROACH ON SURVIVAL OF PATIENTS WITH KLATSKIN TUMOR 101
METRONOMIC CAPECITABINE IN HEPATOCELLULAR CARCINOMA RELAPSE AFTER LIVER TRANSPLANTATION: A RETROSPECTIVE STUDY 100
Intestinal microbiota around colorectal cancer genesis 97
Totale 4.076
Salva come PNG Salva come JPEG
Categoria #
all - tutte 10.452
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 10.452
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/2021271 0 0 0 0 0 14 11 21 43 7 7 168
2021/2022586 63 32 20 29 54 35 18 35 17 37 144 102
2022/2023750 85 111 39 89 44 54 10 47 114 22 75 60
2023/2024254 27 28 2 22 12 88 16 8 5 11 19 16
2024/2025666 35 88 59 63 156 28 39 33 14 43 19 89
2025/2026659 159 72 102 109 184 33 0 0 0 0 0 0
Totale 4.076